November 29, 2024
European Commission Approves BeiGene’s TEVIMBRA for First-Line Treatment of Advanced/Metastatic Esophageal Squamous Cell Carcinoma and Gastric or Gastroesophageal Junction Cancer
TEVIMBRA, tislelizumab, European Commission approval, first-line treatment, esophageal squamous cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, cancer treatment, BeiGene.
Merck and Kelun-Biotech Advance in Cancer Treatment with Exclusive License Agreement for Investigational ADC Candidates
Merck, Kelun-Biotech, Antibody-Drug Conjugates (ADC), Cancer Treatment, Exclusive License Agreement, TROP2, Nectin-4, SKB571